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Abstract
Introduction: Patients suffering from sepsis are currently classified on a clinical basis (i.e., sepsis, severe sepsis, septic
shock); however, this clinical classification may not accurately reflect the overall immune status of an individual patient.
Our objective was to describe a cohort of patients with sepsis in terms of their measured immune status.
Methods: Fifty-two patients with sepsis (n = 13), severe sepsis (n = 21), or septic shock (n = 18) were studied. The
immune status was determined by measuring the CD4+ lymphocyte adenosine triphosphate (ATP) content after
mitogen stimulation in whole blood.
Results: The measured CD4+ lymphocyte ATP content at the time of ICU admission did not differ among the various
groups defined by the sepsis classification system (sepsis = 454 ± 79 ng/ml; severe sepsis = 359 ± 54 ng/ml; septic
shock = 371 ± 53 ng/ml; P = 0.44). Furthermore, survivors of sepsis had a significantly higher CD4+ lymphocyte ATP
content at the time of ICU admission than did nonsurvivors of sepsis (431 ± 41 ng/mL vs. 266 ± 53 ng/mL, respectively;
P = 0.04).
Conclusions: The sepsis classification system that is currently used is not representative of the individual immune
status as determined by measuring the CD4+ lymphocyte ATP content. Moreover, a lower CD4+ ATP content at the
time of ICU admission is associated with a worse clinical outcome in those suffering from sepsis.
Introduction
Sepsis, the systemic inflammatory response syndrome
that results from infection, is associated with considerable mortality. Besides controlling the inciting infectious
insult and providing good supportive care, few therapies
are available to treat this syndrome. Although it seems
conceptually appealing that suppressing the generalized
inflammatory response in sepsis would improve outcomes, the evaluation of numerous adjuvant therapies
has led to conflicting, yet disappointing results [1-3].
Currently, patients suffering from sepsis are classified
based on the presence of organ dysfunction and/or shock
(i.e., sepsis, severe sepsis, septic shock). Although this
classification system is widely used, it may not accurately
reflect the overall immune status of an individual patient
(i.e., hypoimmune, hyperimmune) [4]. This is especially

important because the current sepsis treatment guidelines recommend consideration of the prescription of
immune altering therapy (i.e., corticosteroids) based on
the clinical classification of septic shock [5]. Furthermore,
corticosteroids alter cell-mediated immune function, and
evidence suggests that depressed cell-mediated immune
function is associated with worse clinical outcomes [6-9];
therefore, a biological marker of cell-mediated immune
status could have the potential to improve classification
and risk stratification in sepsis.
We hypothesized that the evaluation of a biomarker
used to determine the cell-mediated immune status
would be informative in a cohort of patients with sepsis.
Furthermore, we hypothesized that their measured
immune status might not be reflective of their sepsis classification. Finally, we hypothesized that their immune status might be associated with mortality.

* Correspondence: MKOLLEF@DOM.wustl.edu
1

Department of Medicine, Washington University in St. Louis School of
Medicine, 660 South Euclid, Campus Box 8052, St. Louis, Missouri 63110, USA

Full list of author information is available at the end of the article
© 2010 Lawrence et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

Lawrence et al. Critical Care 2010, 14:R110
http://ccforum.com/content/14/3/R110

Page 2 of 6

Materials and methods

CD4+ lymphocyte ATP content determination

Patient population and study setting

The Immuknow® assay (Cylex Inc., Columbia, MD, USA)
was used to determine the ATP content of CD4+ lymphocytes and was performed according to the manufacturer's
instructions and previous descriptions [11,12]. Briefly,
100 μL of a 1:4 dilution of whole blood was incubated
with phytohemagglutinin (2.5 μg/mL) for 15 to 18 hours
in a 5% carbon dioxide incubator at 37°C. Anti-human
CD4 monoclonal antibody-coated magnetic particles
(Dynal, Oslo, Norway) were added to select CD4+ cells
after stimulation. After washing the selected CD4+ cells
selected on a strong magnet (Cylex Cat. 1050; Cylex Inc.,
Columbia, MD, USA), a lysing reagent was added to
release intracellular ATP. A luciferin/luciferase mixture
was then added to the cell lysate. Within 30 minutes after
the addition of enzyme, the bioluminescent product was
measured in a luminometer (PHL Mediators, Austria, or
Berthold, Maryville, TN, USA, or Turner Designs, Sunnyvale, CA, USA). The amount of light emitted (emission
maximum 562 nm) was compared with a calibration
curve generated with ATP calibrators (0, 1, 10, 100, and
1,000 ng/mL). The concentration of ATP (ng/mL) in each
sample was then calculated from the calibration curve
using an Excel-based program provided by Cylex
(Columbia, MD, USA). Replicate samples with a calculated percentage coefficient of variation greater than 20%
were included in the calculation if a single value was
within three standard deviations of the mean value of all
wells.

This study was approved by the Institutional Review
Board at Washington University School of Medicine
Human Studies Committee. Patients were enrolled in the
study within 24 hours of admission to the medical ICUs
at Barnes-Jewish Hospital in St. Louis, Missouri. In addition, patients met the criteria for sepsis (n = 13), severe
sepsis (n = 21), or septic shock (n = 18) as defined according to the American College of Chest Physicians/Society
of Critical Care Medicine Consensus Conference [10]. All
patients, or an acceptable surrogate, provided informed
consent to participate in the study.
Patients deemed likely to have a poor outcome, for a
reason known at admission other than sepsis, severe sepsis, or septic shock (i.e., cardiac arrest or widely metastatic cancer) were not enrolled in the study. Patients
were followed until hospital discharge, and their routine
clinical and laboratory data were recorded. All patients
received early goal-directed therapy according to a standard protocol emphasizing adequate volume administration, appropriate antibiotic administration, and optimal
oxygen delivery.
Specimen collection

Blood was collected into sodium heparin tubes (Vacutainer; Becton Dickinson, Franklin Lakes, NJ, USA)
through existing venous catheters in all patients. This collection was performed at serial time points during the
course of each patient's ICU stay. Specifically, blood was
collected at T1 = ICU day 1 (admission), T2 = ICU day 2 to
5, and T3 = ICU day 8 (Figure 1). After collection, the
blood was then transported, at room temperature, to the
laboratory for same day processing. Blood specimens
were collected only during the course of the ICU stay.

Admitted to medical ICU and met inclusion and exclusion criteria N=52

Statistical analysis

All data are presented as the mean ± the standard error of
the mean unless otherwise indicated. All comparisons
were unpaired and all tests of significance were twotailed. SPSS version 11.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Continuous variables were compared using the Mann-Whitney U
test or the Kruskal-Wallis test, where appropriate, for
non-normally distributed variables. The Pearson chisquared was used to compare categorical variables. A Pvalue of less than 0.05 was considered significant.
Role of the sponsor

CD4+ lymphocyte ATP determination within 24 hours of ICU admission (T1) N=52

Expired or discharged from ICU and/or hospital N=19

CD4+ lymphocyte ATP determination within ICU day 2-5 (T2) N=33

Expired or discharged from ICU and/or hospital N=18

The study sponsor, Cylex, Inc., had no role in the design
of the study. They also had no role in the collection or
interpretation of data, and they had no role in the preparation of the manuscript or the decision to submit it for
publication.

Results
Characteristics of the study population

CD4+ lymphocyte ATP determination on ICU day 8 (T3) N=15

Figure 1 Time frame of serial CD4+ lymphocyte ATP content and
patient flow during investigation.

We evaluated 52 patients in our investigation. Overall,
these patients appear representative of typical patients
with sepsis encountered in an ICU setting. Table 1 shows
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Table 1: Characteristics of study population (n = 52)
Characteristic

Value

Age (years)

57 ± 2

Sex, n (%)
Male

27 (52)

Female

25 (48)

Race, n (%)
White

32 (62)

African American

20 (38)

Admitting sepsis classification, n (%)
Sepsis

13 (25)

Severe sepsis

21 (40)

Septic shock

18 (35)

Source of sepsis
Lung

27 (52)

Abdomen (including urinary source)

15 (29)

Blood

5 (10)

Other

5 (10)

Acute Physiology and Chronic Health Evaluation II
Score

22 ± 1

Source of admission
Emergency department

26 (50)

Hospital ward

18 (35)

Other

8 (15)

Length of stay (days)
ICU

5±1

Hospital

13 ± 2

Culture results, n (%)
Positive

34 (65)

Negative

18 (35)

Immune status, n (%)
Immunocompetent

39 (75)

Immunocompromised

13 (25)

the main characteristics of our study population. Thirteen patients were considered to be immunocompromised based on one or more of the following criteria:
HIV positivity, organ transplant recipient, pharmacologic
immunosuppression, recent chemotherapy (within eight
weeks prior to enrollment).
Clinical and laboratory data according to conventional
sepsis classification

Figure 2 demonstrates the CD4+ lymphocyte ATP content according to the conventional sepsis classification at
the time of ICU admission. There was no significant difference in the CD4+ lymphocyte ATP content among

Figure 2 CD4+ lymphocyte ATP content at ICU admission among
patients when grouped according to the sepsis classification system. P = 0.44. Black bars indicate the mean CD4+ lymphocyte ATP content for each group, respectively.

patients when grouped according to this classification
system (sepsis = 454 ± 79 ng/ml; severe sepsis = 359 ± 54
ng/ml; septic shock = 371 ± 53 ng/ml; P = 0.44). In addition, there was no significant difference in the total white
blood cell count among the different groups (sepsis = 16.4
± 3.4 × 103cells/μL; 16.8 ± 2.0 × 103cells/μL; 16.9 ± 2.5 ×
103cells/μL; P = 0.82), and the absolute lymphocyte count
was also not significantly different among the groups (1.9
± 0.9 × 103 cells/μL; 1.0 ± 0.1 × 103 cells/μL; 2.3 ± 1.4 × 103
cells/μL, respectively; P = 0.98). Not surprisingly, the
Acute Physiology and Chronic Health Evaluation
(APACHE) II score did differ among the groups (16.4 ±
1.6; 23.7 ± 1.4; 25.1 ± 2.1, respectively; P = 0.006); however, the mortality difference among the groups did not
reach statistical significance (23.1%; 23.8%; 33.3%, respectively; P = 0.75).
Clinical and laboratory data according to clinical immune
status

The mean CD4+ lymphocyte ATP content differed significantly between the immunocompetent group of patients
and the immunocompromised group of patients (437 ±
38 ng/mL vs. 237 ± 63 ng/mL, respectively; P = 0.01).
However, the total white blood cell count was not significantly different between these groups(16.8 ± 1.4 ×
103cells/μL vs. 16.6 ± 3.9 × 103cells/μL, respectively; P =
0.65), and the absolute lymphocyte count was also not
significantly different (1.3 ± 0.3 × 103 cells/μL vs. 2.7 ± 1.9
× 103 cells/μL, respectively; P = 0.27). Furthermore, the
APACHE II score did not differ between the groups (22.2
± 1.3 vs. 22.9 ± 2.3, respectively; P = 1.00), and the mortality also did not differ significantly (25.6% vs. 30.8%,
respectively; P = 0.73).
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Clinical and laboratory data according to mortality

Table 2 demonstrates the mortality stratified by quartiles
of measured CD4+ lymphocyte ATP content. Clearly
there are differences in the mortality when patients are
stratified in this manner; however, these differences did
not reach statistical significance (P = 0.21). The total
white blood cell count was also not significantly different
between survivors and nonsurvivors (16.4 ± 1.4 vs. 17.5 ±
3.7 × 103cells/μL, respectively; P = 0.87). In addition, the
absolute lymphocyte count was not significantly different
between the survivors and nonsurvivors (2.0 ± 0.7 vs. 0.8
± 0.2 × 103 cells/μL, respectively; P = 0.08). Not surprisingly, the APACHE II score did differ between survivors
and nonsurvivors (19.8 ± 1.0 vs. 29.4 ± 2.3, respectively; P
< 0.0001).
Figure 3 demonstrates the serial measurements of
CD4+ lymphocyte ATP content over time during the ICU
stay grouped according to survivor and nonsurvivor status. There was a significant difference in CD4+ lymphocyte ATP content at admission, T1, between survivors
and nonsurvivors (431 ± 41 ng/mL vs. 266 ± 53 ng/mL,
respectively; P = 0.04). Although differences were noted
in CD4+ lymphocyte ATP content at other time points,
statistical significance was not demonstrated other than
at admission (T1); however, fewer patients were evaluated
at subsequent time points.

Discussion
We have demonstrated that there is a wide range of CD4+
lymphocyte ATP content in a typical ICU population suffering from sepsis. Furthermore, we have demonstrated
that the current sepsis classification (i.e., sepsis; severe
sepsis; septic shock) does not accurately reflect the CD4+
lymphocyte ATP content, and arguably, the immune status of an individual patient. We have also demonstrated
that a lower CD4+ lymphocyte ATP content is associated
with a higher mortality, and most surprisingly, this finding is present at the time of ICU admission.
Measuring CD4+ lymphocyte ATP content after exposure to a stimulus is one method of determining the
global cell-mediated immune response, and this approach
Table 2: Mortality by quartile of CD4+ lymphocyte ATP
content measure at the time of ICU admission
ATP content (ng/mL)

Nonsurvivors/Total

Mortality (%)

≤250

6/13

46

251-500

6/24

25

501-750

2/10

20

≥751

0/5

0

Statistical significance for mortality was P > 0.05 for comparisons
between quartiles.

Figure 3 Serial measurements of CD4+ lymphocyte ATP content
during the course of ICU stay according to survival status. Data are
shown for T1 = ICU day 1, T2 = ICU day 2 to 5, and T3 = ICU day 8. Numbers presented under the horizontal axis represent the number of patients in the survivor and nonsurvivor groups at the different time
points, respectively. * P < 0.05 for T1; P > 0.05 for T2 and T3.

has primarily been used as an aid to guide immunosuppressive therapy in transplant recipients [12,13]. In theory, a biomarker such as this could yield valuable
information in staging the host immune response in the
setting of sepsis, and it could potentially identify those
who could benefit, or be harmed, by a particular intervention [14]. For example, one might surmise that administering a therapy that lowers the immune status (i.e,
corticosteroids) based solely on the presence of shock -when in fact the immune status may already be markedly
suppressed -- could have an undesired effect because of
improper patient selection.
Our data are consistent with previously published
results suggesting that decreased cell-mediated immune
function is associated with a worse prognosis in the setting of sepsis. For example, Heidecke and colleagues
demonstrated that decreased T cell proliferation correlated with mortality in patients with post-operative sepsis
due to intraabdominal infections [8]. Furthermore,
Meakins and colleagues used reactivity to skin testing to
evaluate the host immune response and found decreased
reactivity to be associated with mortality in several
patient populations [9].
Interestingly, data are beginning to accumulate supporting the notion that viruses may reactivate in immunocompetent patients during times of critical illness, and
this reactivation seems to be associated with worse clinical outcomes, including mortality [6,7]. In fact, it is conceivable that these pathogens may represent an
epiphenomenon of an underlying 'acquired immunosuppressed state'; however, this is not to say that these pathogens may not be capable of causing end-organ disease
(i.e., true infections). To further support this notion, the
mean CD4+ lymphocyte ATP content from our sepsis
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nonsurvivors is similar to the reported mean CD4+ lymphocyte ATP content of solid-organ transplant recipients
(266 vs. 282, respectively) [12]. Similarly, the mean CD4+
lymphocyte ATP content from our sepsis survivors is
similar to the reported mean CD4+ lymphocyte ATP
content of healthy controls (431 vs. 432, respectively)
[12].
The reason for why lower CD4+ lymphocyte ATP content is associated with a worse prognosis is strictly speculation, yet interesting. First, this decrease may be due to
mitochondrial dysfunction [15-19]. Second, this decrease
may be due to anergy of the lymphocytes to mitogen
stimulation [8,20]. It should also be noted that this
decrease may simply represent another form of organ
dysfunction -- lymphocyte bioenergetic failure -- in the
setting of sepsis.
Our study has several limitations that should be mentioned. First, the CD4+ lymphocyte counts were not
determined, so the measured CD4+ lymphocyte ATP
content could be an indirect measure of cell number.
However, previous experience using this assay in solidorgan transplant recipients indicates that this is unlikely
to be the case, and we have reported the total lymphocyte
counts, which also support this notion. Also, our small
sample size limits our ability to draw definitive conclusions regarding the use of this assay in staging the host
response to sepsis.
On the other hand, our study also has several strengths.
To our knowledge, this is the first investigation to use this
method in an attempt to stage the host immune response
in sepsis; therefore, our findings are important when
viewed as thought provoking and hypothesis generating.
Furthermore, patients in our study classified as immunocompromised based on clinical criteria had significantly
different assay results than those who were immunocompetent, which is similar to prior published data [12]. This
observed difference further supports the notion that this
assay is an objective marker of the global cell-mediated
immune status of an individual, and therefore, provides
useful information, particularly in the setting of sepsis.
In summary, we have demonstrated that the sepsis classification system that is currently used does not accurately reflect the immune status of an individual when
measured by determining the CD4+ lymphocyte ATP
content. This finding raises the question, 'Is the current
sepsis classification system reliable at determining the
immune status, specifically cell-mediated immune status,
and should this classification system be used to direct
adjuvant immunomodulatory therapy in the setting of
sepsis?'. Furthermore, we have demonstrated that a lower
CD4+ ATP content is associated with a worse clinical
outcome in those suffering from sepsis, and importantly,
this finding is present at the time of ICU admission.
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Conclusions
The sepsis classification system that is currently used is
not representative of the individual immune status as
determined by measuring the CD4+ lymphocyte ATP
content. Moreover, a lower CD4+ ATP content at the
time of ICU admission is associated with a worse clinical
outcome in those suffering from sepsis.
Key messages
• Sepsis is the systemic inflammatory response that
results from an infectious insult.
• Patients with sepsis are currently classified based on
the presence of organ dysfunction and/or shock (i.e.,
sepsis, severe sepsis, septic shock).
• The immune status of an individual patient may not
correlate with the current classification system that is
used to categorize these patients.
• Our data shows no significant difference in the measured immune status of patients based on the current
classification system.
• Patients with sepsis who have lower measures of
immune function at the time of ICU admission
appear to have an increased mortality.
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